Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krischer, J. P.
Right arrow Articles by Lipshultz, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krischer, J. P.
Right arrow Articles by Lipshultz, S. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 15, 1544-1552, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience

JP Krischer, S Epstein, DD Cuthbertson, AM Goorin, ML Epstein and SE Lipshultz
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. jpKrischer@moffitt.usf.edu

PURPOSE: To determine the incidence of clinical cardiotoxicity from anthracycline chemotherapy in children with cancer and to identify associated risk factors. PATIENTS AND METHODS: The study population consisted of 6,493 children with cancer who had received anthracycline chemotherapy on Pediatric Oncology Group (POG) protocols from 1974 to 1990. Cardiotoxicity, defined as congestive heart failure not due to other causes, abnormal measurements of cardiac function that prompted discontinuation of therapy, or sudden death from presumed cardiac causes, was determined by a review of protocol records. RESULTS: Cardiotoxicity was confirmed in 106 patients (1.6%): 58 had congestive heart failure, 43 had changes in measures of cardiac function that prompted the discontinuation of therapy, and five died suddenly from presumed cardiac causes. In a multivariate analysis, factors that contributed to the relative risk (RR) of toxicity were a cumulative anthracycline dose > or = 550 mg/m2 of body-surface area (RR = 5.2), maximal dose > or = 50 mg/m2 (RR = 2.8), female sex (RR = 1.9), black race (RR = 1.7), presence of trisomy 21 (RR = 3.4), and exposure to amsacrine (RR = 2.6). Cardiotoxicity within 1 year after the completion of anthracycline treatment (early cardiotoxicity) represented 89.5% of all cases. CONCLUSION: Early clinical cardiotoxicity in children treated with anthracycline is rare. A high maximal dose, or cumulative dose of anthracycline, female sex, black race, presence of trisomy 21, and treatment with amsacrine increase the risk for anthracycline- associated cardiotoxicity.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
A. C. Xavier and J. W. Taub
Acute leukemia in children with Down syndrome
Haematologica, July 1, 2010; 95(7): 1043 - 1045.
[Full Text] [PDF]

Home page
 JCOHome page
S. E. Lipshultz and M. J. Adams
Cardiotoxicity After Childhood Cancer: Beginning With the End in Mind
J. Clin. Oncol., March 10, 2010; 28(8): 1276 - 1281.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. R. Meacham, E. J. Chow, K. K. Ness, K. Y. Kamdar, Y. Chen, Y. Yasui, K. C. Oeffinger, C. A. Sklar, L. L. Robison, and A. C. Mertens
Cardiovascular Risk Factors in Adult Survivors of Pediatric Cancer--A Report from the Childhood Cancer Survivor Study
Cancer Epidemiol. Biomarkers Prev., January 1, 2010; 19(1): 170 - 181.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. H. O'Donnell and M. E. Dolan
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Clin. Cancer Res., August 1, 2009; 15(15): 4806 - 4814.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Gonzalez-Covarrubias, J. Zhang, J. L. Kalabus, M. V. Relling, and J. G. Blanco
Pharmacogenetics of Human Carbonyl Reductase 1 (CBR1) in Livers from Black and White Donors
Drug Metab. Dispos., February 1, 2009; 37(2): 400 - 407.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. R. Rabin and J. A. Whitlock
Malignancy in Children with Trisomy 21
Oncologist, February 1, 2009; 14(2): 164 - 173.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer
Anthracycline Cardiotoxicity: From Bench to Bedside
J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S. E Lipshultz, J. A Alvarez, and R. E Scully
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Heart, April 1, 2008; 94(4): 525 - 533.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al.
Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
Pediatrics, February 1, 2008; 121(2): e387 - e396.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. M. O'Brien, J. W. Taub, M. N. Chang, G. V. Massey, K. C. Stine, S. C. Raimondi, D. Becton, Y. Ravindranath, and G. V. Dahl
Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421
J. Clin. Oncol., January 20, 2008; 26(3): 414 - 420.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. T. Armstrong, C. A. Sklar, M. M. Hudson, and L. L. Robison
Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter?
J. Clin. Oncol., October 1, 2007; 25(28): 4477 - 4489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. M. Hudson, S. N. Rai, C. Nunez, T. E. Merchant, N. M. Marina, N. Zalamea, C. Cox, S. Phipps, R. Pompeu, and D. Rosenthal
Noninvasive Evaluation of Late Anthracycline Cardiac Toxicity in Childhood Cancer Survivors
J. Clin. Oncol., August 20, 2007; 25(24): 3635 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Fajardo and D. Bernstein
Endocannabinoid Inhibition: A New Cardioprotective Strategy Against Doxorubicin Cardiotoxicity
J. Am. Coll. Cardiol., August 7, 2007; 50(6): 537 - 539.
[Full Text] [PDF]

Home page
 Mol. Interv.Home page
Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St. Clair
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Mol. Interv., June 1, 2007; 7(3): 147 - 156.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M. Belham, A. Kruger, S. Mepham, G. Faganello, and C. Pritchard
Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy
Eur J Heart Fail, April 1, 2007; 9(4): 409 - 414.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Blood, February 1, 2007; 109(3): 896 - 904.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Brouwer, J. Gietema, M. van den Berg, M. Bink-Boelkens, N. Elzenga, J Haaksma, W. Kamps, J. Vonk, E. de Vries, and A Postma
Long-term cardiac follow-up in survivors of a malignant bone tumour
Ann. Onc., October 1, 2006; 17(10): 1586 - 1591.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. Bernstein, G. Fajardo, M. Zhao, T. Urashima, J. Powers, G. Berry, and B. K. Kobilka
Differential cardioprotective/cardiotoxic effects mediated by {beta}-adrenergic receptor subtypes
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2441 - H2449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Lipshultz, S. R. Lipsitz, S. E. Sallan, V. M. Dalton, S. M. Mone, R. D. Gelber, and S. D. Colan
Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol., April 20, 2005; 23(12): 2629 - 2636.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. S. Lakhman, D. Ghosh, and J. G. Blanco
FUNCTIONAL SIGNIFICANCE OF A NATURAL ALLELIC VARIANT OF HUMAN CARBONYL REDUCTASE 3 (CBR3)
Drug Metab. Dispos., February 1, 2005; 33(2): 254 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pediatric Oncology NursingHome page
D. Eshelman, W. Landier, T. Sweeney, A. L. Hester, K. Forte, J. Darling, and M. M. Hudson
Facilitating Care for Childhood Cancer Survivors: Integrating Children's Oncology Group Long-Term Follow-Up Guidelines and Health Links in Clinical Practice
Journal of Pediatric Oncology Nursing, September 1, 2004; 21(5): 271 - 280.
[Abstract] [PDF]

Home page
 JCOHome page
J. P. Ginsberg, A. Cnaan, H. Zhao, B. J. Clark, S. M. Paridon, A. J. Chin, J. Rychik, A. N. Hogarty, G. Barber, M. Rutkowski, et al.
Using Health-Related Quality of Life Measures to Predict Cardiac Function in Survivors Exposed to Anthracyclines
J. Clin. Oncol., August 1, 2004; 22(15): 3149 - 3155.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Lipshultz, N. Rifai, V. M. Dalton, D. E. Levy, L. B. Silverman, S. R. Lipsitz, S. D. Colan, B. L. Asselin, R. D. Barr, L. A. Clavell, et al.
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
N. Engl. J. Med., July 8, 2004; 351(2): 145 - 153.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. Marina, M. Gebhardt, L. Teot, and R. Gorlick
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Oncologist, July 1, 2004; 9(4): 422 - 441.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
E. Huettemann, T. Junker, K. P. Chatzinikolaou, G. Petrat, S. G. Sakka, L. Vogt, and K. Reinhart
The Influence of Anthracycline Therapy on Cardiac Function During Anesthesia
Anesth. Analg., April 1, 2004; 98(4): 941 - 947.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. M. Mone, M. W. Gillman, T. L. Miller, E. H. Herman, and S. E. Lipshultz
Effects of Environmental Exposures on the Cardiovascular System: Prenatal Period Through Adolescence
Pediatrics, April 1, 2004; 113(4/S1): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. Silber, A. Cnaan, B. J. Clark, S. M. Paridon, A. J. Chin, J. Rychik, A. N. Hogarty, M. I. Cohen, G. Barber, M. Rutkowski, et al.
Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to Anthracyclines
J. Clin. Oncol., March 1, 2004; 22(5): 820 - 828.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
K. B. Wallace, E. Hausner, E. Herman, G. D. Holt, J. T. Macgregor, A. L. Metz, E. Murphy, I.Y. Rosenblum, F. D. Sistare, and M. J. York
Serum Troponins as Biomarkers of Drug-Induced Cardiac Toxicity
Toxicol Pathol, January 1, 2004; 32(1): 106 - 121.
[PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Heon, M. Bernier, N. Servant, S. Dostanic, C. Wang, G. M. Kirby, L. Alpert, and L. E. Chalifour
Dexrazoxane does not protect against doxorubicin-induced damage in young rats
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H499 - H506.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn
Advances in the Diagnosis and Treatment of Neuroblastoma
Oncologist, June 1, 2003; 8(3): 278 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Limat, K. Demesmay, L. Voillat, Y. Bernard, E. Deconinck, A. Brion, A. Sabbah, M. C. Woronoff-Lemsi, and J. Y. Cahn
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
Ann. Onc., February 1, 2003; 14(2): 277 - 281.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Avvisati, M. C. Petti, F. Lo-Coco, M. L. Vegna, S. Amadori, M. Baccarani, N. Cantore, E. Di Bona, F. Ferrara, G. Fioritoni, et al.
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
Blood, October 16, 2002; 100(9): 3141 - 3146.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Goodin and R. Cunningham
5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile
Oncologist, October 1, 2002; 7(5): 424 - 436.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. D. McCollum, P. J. Catalano, D. G. Haller, R. J. Mayer, J. S. Macdonald, A. B. Benson III, and C. S. Fuchs
Outcomes and Toxicity in African-American and Caucasian Patients in a Randomized Adjuvant Chemotherapy Trial for Colon Cancer
J Natl Cancer Inst, August 7, 2002; 94(15): 1160 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Perel, A. Auvrignon, T. Leblanc, J.-P. Vannier, G. Michel, B. Nelken, V. Gandemer, C. Schmitt, J.-P. Lamagnere, L. De Lumley, et al.
Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91
J. Clin. Oncol., June 15, 2002; 20(12): 2774 - 2782.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
M.I. Gharib and A.K. Burnett
Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis
Eur J Heart Fail, June 1, 2002; 4(3): 235 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. V. Jensen, T. Skovsgaard, and S. L. Nielsen
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients
Ann. Onc., May 1, 2002; 13(5): 699 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. C. M. Kremer, E. C. van Dalen, M. Offringa, and P. A. Voute
Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review
Ann. Onc., February 1, 2002; 13(4): 503 - 512.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. L. Keefe
The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern?
Oncologist, February 1, 2002; 7(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe
Acute promyelocytic leukemia: evolving therapeutic strategies
Blood, February 1, 2002; 99(3): 759 - 767.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Green, Y. A. Grigoriev, B. Nan, J. R. Takashima, P. A. Norkool, G. J. D'Angio, and N. E. Breslow
Congestive Heart Failure After Treatment for Wilms' Tumor: A Report From the National Wilms' Tumor Study Group
J. Clin. Oncol., April 1, 2001; 19(7): 1926 - 1934.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, et al.
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
J. Clin. Oncol., March 1, 2001; 19(5): 1444 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. C.M. Kremer, E. C. van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voute
Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
J. Clin. Oncol., January 1, 2001; 19(1): 191 - 196.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Lipshultz, M. A. Grenier, S. D. Colan, A. D. Ginsburg, S. M. Swain, F. M. Muggia, J. L. Speyer, P. K. Singal, C. L.M. Olweny, and T. Li
Doxorubicin-Induced Cardiomyopathy
N. Engl. J. Med., February 25, 1999; 340(8): 653 - 655.
[Full Text]

Home page
 The OncologistHome page
J. E. Rubnitz and C.-H. Pui
Childhood Acute Lymphoblastic Leukemia
Oncologist, December 1, 1997; 2(6): 374 - 380.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online